Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Shares Issued (2018 - 2025)

Arcturus Therapeutics Holdings' Shares Issued history spans 8 years, with the latest figure at $11.7 million for Q4 2025.

  • For Q4 2025, Shares Issued rose 8631.34% year-over-year to $11.7 million; the TTM value through Dec 2025 reached $12.3 million, up 159.4%, while the annual FY2025 figure was $11.7 million, 146.79% up from the prior year.
  • Shares Issued reached $11.7 million in Q4 2025 per ARCT's latest filing, up from $116000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $11.7 million in Q4 2025 to a low of -$716000.0 in Q4 2023.
  • Average Shares Issued over 5 years is $1.1 million, with a median of $257000.0 recorded in 2022.
  • Peak YoY movement for Shares Issued: crashed 1010.0% in 2022, then soared 8631.34% in 2025.
  • A 5-year view of Shares Issued shows it stood at $387000.0 in 2021, then crashed by 147.03% to -$182000.0 in 2022, then tumbled by 293.41% to -$716000.0 in 2023, then skyrocketed by 118.72% to $134000.0 in 2024, then skyrocketed by 8631.34% to $11.7 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Shares Issued are $11.7 million (Q4 2025), $116000.0 (Q3 2025), and $274000.0 (Q2 2025).